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Abstract
Spinocerebellar ataxia type 14 (SCA-PRKCG, formerly SCA14) is a rare, slowly progressive disorder caused by conventional
mutations in protein kinase Cγ (PKCγ). The disease usually manifests with ataxia, but previous reports suggested PRKCG
variants in retinal pathology. To systematically investigate for the first time visual function and retinal morphology in patients
with SCA-PRKCG. Seventeen patients with PRKCG variants and 17 healthy controls were prospectively recruited, of which 12
genetically confirmed SCA-PRKCG patients and 14matched controls were analyzed. We enquired a structured history for visual
symptoms. Vision-related quality of life was obtained with the National Eye Institute Visual Function Questionnaire (NEI-VFQ)
including the Neuro-Ophthalmic Supplement (NOS). Participants underwent testing of visual acuity, contrast sensitivity, visual
fields, and retinal morphology with optical coherence tomography (OCT). Measurements of the SCA-PRKCG group were
analyzed for their association with clinical parameters (ataxia rating and disease duration). SCA-PRKCG patients rate their
vision-related quality of life in NEI-VFQ significantly worse than controls. Furthermore, binocular visual acuity and contrast
sensitivity were worse in SCA-PRKCG patients compared with controls. Despite this, none of the OCT measurements differed
between groups. NEI-VFQ and NOS composite scores were related to ataxia severity. Additionally, we describe one patient with
a genetic variant of uncertain significance in the catalytic domain of PKCγ who, unlike all confirmed SCA-PRKCG, presented
with a clinically silent epitheliopathy. SCA-PRKCG patients had reduced binocular vision and vision-related quality of life. Since
no structural retinal damage was found, the pathomechanism of these findings remains unclear.
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Introduction
The spinocerebellar ataxias (SCA) denote the group of autoso-
mal dominantly inherited ataxias clinically characterized by
cerebellar syndrome and non-cerebellar involvement of varying
degrees [1, 2]. The first genetically identified SCAs were
caused by repeat-expansion mutations, and their phenotypes
have been well described in large cohort studies (e.g.,
EUROSCA) [3–6]. SCA-PRKCG (formerly SCA14) was one
of the first SCAs in which a conventional mutation was de-
scribed as causative [7]. Its estimated incidence is 1 to 4% in
ataxia populations with the more common SCA genotypes ex-
cluded [8]. SCA-PRKCG displays a considerable variability in
age of onset. However, as life span is not shortened and the
majority of people remain ambulatory until senectitude, it is
considered a mild, slowly progressive disorder with few non-
ataxia symptoms [9]. The protein kinase C gamma (PKCγ) is
only expressed in neurons of the brain and the spinal cord and is
particularly abundant in Purkinje cells [10]. Nonetheless, it also
exhibits distinct dissemination in the visual system [11–15],
especially in the human retina [14, 15]. In postmortem human
retinas, PKCγ could only be stained in one rare type of gangli-
on cells and two different amacrine cell types [16]. PKCγ ful-
fills various functions in the visual system; for instance, it is an
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oxidative stress sensor in the lens and retina [12, 17], and it
regulates rod photoreceptor differentiation [18] and plays an
essential role in the signaling cascade of the vascular endothe-
lial growth factor (VEGF)–dependent retinal neovasculariza-
tion [19]. Additionally, PKCγ-knockout mice show an enlarged
ganglion cell and inner nuclear layer, which was histologically
caused by empty spaces between cells [17].
Reduced vision-related quality of life has been observed in
the most common SCAs [20]. Visual impairment in SCAs may
be an expression of oculomotor dysfunction which can occur as
part of the cerebellar syndrome or sign of extra-cerebellar in-
volvement [21, 22]. Furthermore, disease-specific involvement
of the afferent visual system has been shown in some SCAs,
most prominently in SCA-ATXN7 (formerly SCA7) where
cone-rod-dystrophy is part of the clinical syndrome [23].
Also, more subtle changes like reduced visual acuity or retinal
changes have been shown in some SCAs [24–26]. While
PRKCG had been assumed to be the locus of autosomal dom-
inant retinitis pigmentosa type 11 (Rp11) by Al-Maghtheh
et al., further analysis could rule out a pathogenic role of
PRKCG in Rp11 [27, 28]. We therefore aimed to comprehen-
sively investigate visual impairment and affection of the affer-
ent visual system in SCA-PRKCG. Data on visual function in
SCA-PRKCG have to date only been reported in three affected
members of one SCA-PRKCG family who had been evaluated
using visually evoked potentials (VEP) and funduscopy. While
funduscopy depicted several regions of retinal degeneration in
one eye of a 21-year-old girl, these findings were not consistent
with an inherited retinal degeneration and not seen in the two
other family members [29].
The National Eye Institute Visual Function Questionnaire
(NEI-VFQ) is a well-established questionnaire to assess clin-
ically important aspects of vision-related quality of life [30]
and has shown good correlation to well-recognized endpoints
in ophthalmologic and neurologic diseases such as multiple
sclerosis or neuromyelitis optica spectrum disorders [31, 32].
NEI-VFQ revealed a significant reduction in vision-related
quality of life in patients suffering from SCA-ATXN1, SCA-
ATXN3, or SCA-CACNA1A. Visual impairment was not on-
ly evident regarding NEI-VFQ composite score but also in
most of the subscores [20].
Optical coherence tomography (OCT) has been used as a
non-invasive and easily applicable tool to evaluate structural
changes of the retina and optic nerve in a wide spectrum of
neurodegenerative diseases including the most common trinu-
cleotide expansion SCAs, particularly in SCA-ATXN1 [33],
SCA-ATXN3 [34], SCA-ATXN7 [23], or a mixed SCA co-
hort (SCA-ATXN1,2,3 or SCA-CACNA1A) [26]. The meth-
od has a spatial resolution comparable with histological prep-
arations [35], can detect subtle changes in retinal architecture,
and is now considered an early biomarker in various
neuroinflammatory and neurodegenerative diseases [36–39].
Furthermore, OCT may be a powerful tool in differentiating
diseases with similar clinical characteristics or work as a sur-
rogate marker for disease stage and severity [40–43]. The aim
of this study was to investigate visual function as well as
structural change in the afferent visual system in patients with
SCA-PRKCG compared to age-matched controls.
Methods
Ethics Statement
The study was conducted in accordance with the Declaration
of Helsinki in its currently applicable version and applicable
German laws. It was approved by the ethics committee of
Charité Universitätsmedizin Berlin and all participants gave
informed written consent.
Participants
Data were derived from a multimodal, cross-sectional, multi-
center, observational study, in which patients and healthy con-
trols (HCs) of comparable age and sex were recruited to better
characterize the clinical profile of SCA-PRKCG. Details were
described elsewhere [44, 45]. The study considered patients
aged > 18 years with ataxia and a variant in the PRKCG gene.
For inclusion into the analysis, variants had to be re-classified
by protein modeling as at least likely pathogenic using a clas-
sification approach modified from Richards et al. [45, 46].
HCs of similar age were recruited among the patients’ envi-
ronment or were other volunteers.
For the visual substudy, we screened 17 patients with ataxia
and PRKCG variant and 17 HC between November 2012 and
April 2014. For analysis, we excluded participants with a
known history of ophthalmologic diseases that could poten-
tially influence the OCT and visual outcomes. Two ataxia
patients were excluded because their variants were re-
classified as benign. We report in the supplement the results
of one patient who carried a variant of uncertain significance
(VUS) in the kinase domain of SCA-PRKCG and one other
confirmed SCA-PRKCG patient with glaucoma. Reasons for
exclusion are summarized in Fig. 1.
Clinical Examination
All tests were carried out by trained examiners within 1 day
per participant. Structured history taking covered the need of
refractive error correction and conditions potentially interfer-
ing with visual assessment (diabetes, arterial hypertension,
cataract, glaucoma).
Clinical examination was performed by trained movement
disorder specialists and included the 8-item scale for assessment
and rating of ataxia (SARA) [47] to evaluate ataxia severity and
the oculomotor items of the inventory of non-ataxia signs
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(INAS) [48], oscillopsia, and onset and severity of diplopia.
Disease onset was defined as the onset of progressive gait
disturbance.
Vision-Related Quality of Life
Every participant completed the German version of the
“National Eye Institute – Visual Function Questionnaire”
(NEI-VFQ) in a self-administered manner [49]. This includes
the 25 basic questions of NEI-VFQ as well as the 14 questions
of the appendix and the 10-Item Neuro-Ophthalmic
Supplement (NOS) developed by Raphael et al. [50].
Subscales include general health, general vision, well-being,
ocular pain, near-, distance-, color-, and peripheral vision,
social functioning, driving, role-limitation, and dependency
whereas the NOS focuses on difficulties due to visual field
defects, unusual eyelids, blurred vision/diplopia, and different
vision of both eyes. Test results were recoded and subscores
were averaged as described in detail in the NEI-VFQ manuals
[51, 52] or according to the guidelines for NOS published by
Wagenbreth et al. [53], respectively. The NOS composite
score represents the unweighted average of all ten NOS items,
while the total composite score is the result of the unweighted
average of all ten NOS items and 24 items of NEI-VFQ, ex-
cept the “general health” score. When participants gave an
invalid answer to an item (no answer, two answers, not able
to answer the question), the respective subscore was computed
only for the participants who gave correct answers.
Visual Function Testing
Visual acuity and contrast sensitivity were assessed on the
OPTEC 6500 P system (Stereo Optical Co, Inc., IL, USA)
under habitual correction using photopic conditions (target
luminance value = 85 cd/m2) without glare. Early Treatment
Diabetic Retinopathy Study (ETDRS) charts were used for
high-contrast visual acuity (HCVA) testing and Functional
Acuity Contrast Test (FACT) for contrast sensitivity testing.
HCVAwas tested both monocular and binocular, and contrast
sensitivity only binocular as this is suggested to represent the
every-day vision [54, 55]. HCVA results were converted into a
logarithm of the minimal angle of resolution scores
(logMAR). Contrast sensitivity results were expressed as area
under the curve as described earlier [56].
Visual Field Analysis
Monocular visual fields were assessed by automated
Humphrey Field Analyzer II 720 (HFA, Zeiss Meditec AG)
with integrated automated Glaucoma Hemifield Test (GHT)
using the 30-2 protocol.
Because of poor reliability indices in the ataxia cohort, we
do not report visual field parameters in the results.
Optical Coherence Tomography
All participants underwent retinal examination with a
Spectral-Domain-OCT (Spectralis, Heidelberg Engineering,
Heidelberg, Germany) with an integrated scanning laser oph-
thalmoscope (SLO) and activated eye tracker. Scans were car-
ried out without pupil dilatation by four operators always
using the same device with normal room illumination.
For peripapillary retinal nerve fiber layer (pRNFL) thick-
ness measurements, a 3.4-mm diameter ring scan (12°, 1536
A-scans, 16 ≤ART≤ 100) centered on the optic nerve head
was used. We analyzed the global thickness of the ring, and
Fig. 1 Inclusion and exclusion of patients. Participants were recruited from a multimodal, cross-sectional, multicenter, observational study. Participants
with known current ophthalmologic diseases were excluded. Only patients with verified mutations in PRKCG were included for statistical analysis
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the thickness of the four quadrants, nasal, temporal, superior,
inferior, and the papillomacular bundle as well as the nasal to
temporal pRNFL thickness (N/T) ratio. Ring scan parameters
are illustrated in Fig. 2a.
Furthermore, a macular volume scan was assessed
(25°×30°, 61 vertical B-scans, 768 A-scans per B-scan,
ART = 12). Macular scans underwent automatic intra-retinal
segmentation with software provided by the manufacturer
(Eye Explorer 1.8.6.0 with viewing module 5.8.3.0). Besides
the total macular volume, the combined ganglion cell, and the
inner plexiform layer, the inner nuclear layer as well as outer
retinal layers including all layers from the outer plexiform
layer to the Bruch membrane were extracted within a 6-mm-
diameter circle around the fovea. Figure 2b depicts all ana-
lyzed layers.
All scans were carefully checked for sufficient scan quality
and accurate segmentation as described elsewhere [57] by one
experienced grader, who was blinded for the group. All im-
ages met the OSCAR IB criteria for image quality [57].
Segmentation was manually corrected if necessary.
OCT images and their corresponding scanning laser
ophthalmoscope fundus images were screened for abnor-
malities or pathologies by experienced physicians and
optometrists. Patients with abnormal image features
were additionally evaluated by an ophthalmologist.
OCT results were reported according to the APOSTEL
recommendations [58].
Statistical Analysis
Statistical analysis was carried out using SPSS 22 (IBM,
Armonk, NY) software. Demographic differences between
patients and HC were analyzed using an independent sam-
ple Mann-Whitney U test (MWU) for age and a 2-sided
chi2 test for sex. NEI-VFQ and NOS analysis included
descriptive data analysis and MWU for between-group
comparisons. The beeswarm plots were created using R
software version 3.6.1, RStudio Version 1.2.1335, and
ggplot2/ggpubr as data visualization packages. We used
generalized estimation equation models (GEEs) account-
ing for within-subject inter-eye effects for group compar-
isons of monocular visual acuity and OCT. The working
correlation matrix was defined as exchangeable. In the
second step of the analysis, we investigated associations
of disease severity (SARA score) with quality of life
scores and results of binocular visual acuity test using
Spearman’s rho test. We further analyzed a possible asso-
ciation of ataxia severity to each OCT measure using GEE
which takes into account the inclusion of individual data
from both eyes. A p value < 0.05 was established as sig-
nificant. We made no adjustments for multiple compari-
sons due to the exploratory nature of the study.
Results
After consideration of exclusion criteria, twelve SCA-
PRKCG patients (9 members of 4 families and 3 singular
cases) and 14 HC were available for analysis (Fig. 1). All
patients exhibited mutations in exon 1–4, i.e., within the reg-
ulatory domain of PRKCG. Demographic, clinical, and func-
tional visual outcomes are presented in Table 1. Groups did
not differ in age or sex. A more detailed overview of the
individual results regarding patient history, visual acuity test,
fundus imaging, and clinical parameters (disease duration/se-
verity, variant) is provided in the supplement (supplement
Table 1; supplement Table 2 lists all individual OCT results).
In the self-reported visual history, one patient reported an
eye infection of unknown etiology earlier in his life and an-
other patient reported ocular pain of unknown origin. In the
clinical examination, all patients displayed saccadic eye
movements and the majority had dysmetric saccades while
some sort of gaze-evoked nystagmus was less frequently seen.
Deficits in the vestibulo-ocular reflex (VOR) were only seen
in two patients while nearly all patients had a disturbed VOR
suppression on fixation. Seven out of 12 patients suffered
from diplopia rated as moderate in two and as severe/
constant in one patient. Some difficulty in horizontal or verti-
cal gaze was seen in two SCA-PRKCG patients, though one
of them was excluded from analysis due to glaucoma.
As a group, patients had a significantly worse vision-
related quality of life in NEI-VFQ compared to HC. Their
results were particularly poor for near, distance, and peripheral
vision. Figure 3 visualizes the results of all NEI-VFQ
subscores. In the NOS, patients reported more difficulties
when eyes are tired than HC (p = 0.004), while no other
NOS subscore reached significance. NOS subscores together
with the composite scores of NEI-VFQ, NOS, and a total
composite score of both are summarized in Table 2.
Visual acuity testing revealed poorer results for SCA-
PRKCG patients compared with that for HC in binocular vi-
sual acuity and binocular contrast sensitivity, while monocular
test results showed no significant difference between groups.
The results of OCT parameters are summarized in Table 3.
We compared pRNFL thickness of all quadrants and the
papillomacular bundle in the peripapillary ring scan and layer
thickness parameters of the ganglion cell and inner plexiform
layer, inner nuclear layer, outer retinal layers, and total macu-
lar volume from the macular scans. Neither in peripapillary
nor in macular analysis was there a significant difference be-
tween both groups.
Among the 12 SCA-PRKCG patients, 3 had remarkable
abnormalities in SLO fundus images (an overview is given
in Supplement Table 1). Among those was one young patient
who showed an unspecific but remarkable tortuosity of the
retinal arteries in both eyes (Fig. 4a). The other findings were
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drusen and calcifying exudates which are both very common
in elderly patients.
Remarkably, the single patient with a variant re-classified
as VUS displayed a clinically silent epitheliopathy of un-
known origin in both eyes (Fig. 4b) that was not seen in any
of the confirmed SCA-PRKCG patients.
Patients with higher ataxia scores had also a lower
vision-related quality of life (rho = − 0.787, p = 0.002)
(Fig. 5). Especially the subscores general vision (rho = −
0.641, p = 0.025), near vision (rho = − 0.715, p = 0.009),
and distance vision (rho = − 0,786, p = 0.002) were worse
in more severely affected patients. There was no associa-
tion of disease severity neither to NOS scores nor to vi-
sual acuity (monocular/binocular HCVA and LCVA).
Furthermore, these parameters of visual acuity did not
show any significant correlation to NEI-VFQ scores.
Exploratory analysis revealed only weak effects of ataxia
severity scores with higher scores (more severe ataxia)
related to thinner total macular volume (p = 0.043, B = −
0.045) and outer retinal layers (p = 0.043, B = − 0.715),
Table 1 Cohort overview and
functional visual outcomes SCA-PRKCG HC p
Total 12 14
Sex
Male 6 8 0.716 (Chi2)
Female 6 6
Age/years
Mean ± SD 51.75 ± 13.6 50.7 ± 11.1 0.820 (MWU)
Range 29–70 30–65
Disease duration
Years, mean ± SD 20.7 ± 13.7
Range 0–44
SARA score
Mean ± SD 11.4 ± 3.6
Range 6.5–20.5
Visual acuity
Logmar score monocular ± SD 0.04 ± 0.14 − 0.02 ± 0.10 0.137 (GEE)
Logmar score binocular ± SD − 0.03 ± 0.12 − 0.13 ± 0.82 0.036 (MWU)
FACTAULCSF binocular ± SD 1.92 ± 0.15 2.11 ± 0.06 p < 0.001 (MWU)
Values for both groups are mean ± standard deviation. Significant p values are printed in italics
AULCSF area under the log contrast sensitivity function, HC healthy control, FACT Functional Acuity Contrast
Test, GEE generalized estimation equation models, logMAR logarithm of the minimal angle of resolution,MWU
Man-WhitneyU test, SARA scale for the assessment and rating of ataxia, SCA-PRKCG spinocerebellar ataxia type
14, SD standard deviation
Fig. 2 Illustration of OCT parameters. a Peripapillary ring scan.
Peripapillary ring scan measures retinal nerve fiber layer (RNFL)
thickness within the whole circle, in the quadrants S(uperior), N(asal),
I(nferior), and T(emporal) and in the papillomacular bundle (PMB). The
ratio of nasal to temporal RNFL thickness (N/T ratio) is calculated
automatically. b Layer segmentation analysis. Layer segmentation
analysis was performed within a 6-mm-diameter circle around the
fovea. We measured thickness of the following layers: RNFL (mRNFL)
(macular), the combined ganglion cell and inner plexiform layer
(GCIPL), and the inner nuclear layer (INL) and outer retinal layers
(ORL) including all layers from the outer plexiform layer to the Bruch
membrane. The sum of all these layers adds up to the total macular
volume (TMV).
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whereas no effects were seen on pRNFL. However, the
inspection of respective plots (Fig. 6) suggested that this
was due to the lower values in the one (elderly) subject
with high SARA score.
We found no associations between one distinct oculomotor
deficit and low vision-related quality of life, high rate of fix-
ation loss in visual field testing, or lower binocular visual
acuity. Specifically, the patients with moderate to severe
Fig. 3 a–l Results of NEI-VFQ
and Neuro-Ophthalmologic
Supplement. Comparison of
vision-related quality of life
results in all NEI-VFQ subscales
between SCA-PRKCG and HC.
The y-axis represents the result of
the particular NEI-VFQ subscore,
each scored in a range of 0–100.
NEI-VFQ, National Eye Institute
Visual Function Questionnaire;
SCA-PRKCG, spinocerebellar
ataxia type 14; HC, healthy
control
Table 2 Neuro-Ophthalmic
Supplement (NOS) and
composite scores
NOS subscale SCA-PRKCG (n = 12) HC (n = 14) p
Difficulty when eyes tired 56.3 ± 21.7 80.3 ± 14.5 0.004
Difficulty in bright sunlight 72.9 ± 34.5 87.5 ± 13.0 0.494
Difficulty parking a car 63.9 ± 48.6/n = 9 83.9 ± 36.2 0.369
Difficulty using a computer 83.3 ± 16.3 94.6 ± 10.6 0.095
Two eyes see different 58.3 ± 41.7 78.6 ± 27.5 0.274
Eyelid appearance unusual 87.5 ± 22.6 92.9 ± 18.2 0.667
Vision blurry, not clear, “fuzzy” 81.3 ± 15.5 91.1 ± 12.4 0.145
Trouble focusing on moving objects 79.2 ± 27.9 98.2 ± 6.7 0.060
Binocular double vision 70.8 ± 36.7 96.4 ± 9.1 0.085
Ptosis 95.8 ± 9.7 92.9 ± 26.7 0.742
10-item NOS composite score 75.1 ± 18.9 89.6 ± 8.9 0.013
NEI-VFQ composite score 79.4 ± 15.1 92.6 ± 4.2 < 0.001
Total composite score 77.3 ± 16.6 91.0 ± 5.1 0.001
Values for both groups are means ± standard deviation. Significant p values (resulting from the Mann-Whitney U
test) are printed in italics.
HC healthy control, NOS Neuro-Ophthalmic supplement, NEI-VFQ composite score: National Eye Institute –
Visual Function Questionnaire composite score (without NOS), Total composite score composite of NEI-VFQ
and NOS
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diplopia nevertheless had a low rate of fixation loss and good
visual acuity results.
Discussion
To the best of our knowledge, this is the first study to system-
atically evaluate visual system changes in patients with SCA-
PRKCG. We found that (1) vision-related quality of life was
lower in SCA-PRKCG patients compared with that in HC,
particularly for the items near-, distance-, and peripheral vi-
sion. Furthermore, the impairment in vision-related quality of
life was correlated with ataxia severity, measured by SARA
score, which means that patients with higher SARA scores
had a worse vision-related quality of life. (2) Visual acuity
was worse in the SCA-PRKCG group regarding binocular
high- and low-contrast visual acuity testing and none of the
oculomotor deficits alone accounts for the results above. (3)
We did not find significant changes in retinal layer thickness
in SCA-PRKCG compared with HC. Exploratory analysis
revealed only weak associations of higher SARA scores and
lower total macular volume and outer retinal layers mainly
based on one elderly individual with high SARA score.
Thus, in contrast to other SCA genotypes, our results do not
support retinal thinning or retinal dysfunction (as indicated by
monocular testing of visual acuity) as a prevalent or disease-
specific finding in SCA-PRKCG.
In order to explain the reduced (binocular) visual function
in SCA-PRKCG patients, we checked the individual visual
acuity and contrast sensitivity results. According to the
International Council of Ophthalmology recommendations,
only 3/12 patients had a “mild visual loss” in binocular visual
acuity, defined as visual acuity value ≤ 0.8 decimal (logMAR
score ≥ 0.1) [59] while none of the patients showed moderate
Table 3 Retinal thickness measurements from OCT
Parameter HC (n = 14), mean ± SD Min–max SCA-PRKCG (n = 12), mean ± SD Min–max p GEE
Peripapillary ring scan
Average pRNFL (μm) 100.0 ± 6.3 89–114 101.8 ± 8.1 86–114 0.507
Superior pRNFL (μm) 117.1 ± 11.9 97–146 121.25 ± 15.4 92–151 0.369
Temporal pRNFL (μm) 72.0 ± 10.5 54–98 69.1 ± 13.3 52–112 0.455
Inferior pRNFL (μm) 130.1 ± 9.8 113–150 138.25 ± 16.0 115–178 0.082
Nasal pRNFL (μm) 80.8 ± 11.3 61–103 78.8 ± 12.0 54–104 0.606
RNFL-PMB (μm) 55.5 ± 7.0 44–69 53.3 ± 9.3 41–82 0.403
N/T ratio 1.15 ± 0.24 0.62–1.72 1.19 ± 0.33 0.62–1.77 0.635
Macular volume scan
TMV (mm3) 8.75 ± 0.18 8.40–9.11 8.81 ± 0.31 8.00–9.38 0.594
mRNFL (μm) 36.7 ± 3.1 30.1–41.7 34.8 ± 2.8 30.1–39.3 0.085
GCIPL (μm) 70.0 ± 3.6 63.0–74.6 72.3 ± 6.2 61.9–84.5 0.263
INL (μm) 33.3 ± 2.3 29.7–38.6 34.3 ± 2.8 30.1–42.4 0.313
ORL (μm) 169.6 ± 6.9 156.3–183.2 170.1 ± 5.8 158.1–177.9 0.834
Values for both groups are mean ± standard deviation
GCIPL ganglion cell and inner plexiform layer, INL inner nuclear layer,mRNFLmacular retinal nerve fiber layer, N/T ratio nasal to temporal ratio,OCT
optical coherence tomography, ORL outer retinal layers from outer plexiform layer to Bruch’s membrane, PMB papillomacular bundle, pRNFL
peripapillary retinal nerve fiber layer, SD standard deviation, TMV total macular volume
Fig. 4 Retinal findings in two patients. a Scanning laser ophthalmoscope
image (SLO) (left) and correspondingOCTcross-section (right) of the left
eye of patient 16. Both eyes of this patient displayed an epitheliopathy of
unknown origin. Note that this patient was excluded from statistical
analysis because of unverified SCA-PRKCG diagnosis. b SLO image
(left) and corresponding OCT cross-section (right) of patient 3, who
showed marked tortuosity in both eyes. As this is the only patient of
our cohort exhibiting unexplained tortuosity, we considered this not
disease-associated
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visual acuity deficits. Because of the small sample size, we
cannot rule out that group differences in visual acuity tests are
based on a selection bias towards a HC group with above-
average visual function. Non-significant age differences to
the disadvantage of the SCA-PRKCG group may contribute
to worse visual acuity results in the SCA group. Furthermore,
testing was performed with habitual corrections. Thus, the
slight differences in binocular visual acuity alone would not
present a valid sign of visual impairment. However, there is a
substantial and highly significant difference in binocular con-
trast sensitivity between groups (AULCSF, 1.92 ± 0.15 in
SCA-PRKCG vs. 2.11 ± 0.06 in HC, p < 0.001). Individual
contrast sensitivity results of PRKCG-patients are in the range
of earlier studies in multiple sclerosis cohorts (with about half
with a history of optic neuritis) [56]. Furthermore, results al-
most perfectly distinguish PRKCG patients from HC so that a
mere effect of selection bias is unlikely.
From a clinical point of view, it seems most probable that
reduced visual acuity on binocular testing is associated with
lower vision-related quality of life (VRQoL). However, such
correlations could not be confirmed in our small sample.
Hence, we will discuss three lines of argument as possible
explanations for reduced (binocular) visual acuity and contrast
sensitivity in SCA-PRKCG along with unimpaired monocular
visual acuity: (1) technical issues, (2) affection of the visual
pathway, and (3) an influence of the cerebellar disorder. Later
on, we discuss factors influencing VRQoL independently.
Technical issues might have influenced visual acuity re-
sults. In our study, visual acuity testing was performed habit-
ually and not under best correction. Therefore, a stronger in-
fluence of an uncorrected refractive error in the patient group
is possible.
Despite taking patients’ history of ophthalmologic dis-
eases, we cannot completely rule out that other ocular diseases
such as glaucoma might have caused worse visual outcomes
in the PRKCG cohort. However, we did exclude patients with
a known history of glaucoma (one in both groups) and there
was no RNFL thinning in the SCA-PRKCG suggestive of
glaucoma. Furthermore, cognitive impairment and mood dis-
orders are potential confounders for worse visual acuity tests
both of which were prevalent in the SCA-PRKCG cohort.
Visual acuity tests particularly depend on the information pro-
cessing speed [60]. In fact, all patients with markedly low-
contrast sensitivity scores had mood disorders or cognitive
impairment to some degree (personal communication on the
Fig. 5 a–c Vision-related quality of life and disease severity. Disease
severity (measured by SARA score) correlated inversely to both
questionnaires for vision-related quality of life. Distance vision was
especially worse in SCA-PRKCG patients and showed fair correlation
to disease severity, too
Fig. 6 SARA scores and retinal layer thickness. Scatter plots for OCT
measures versus SARA (ataxia severity) for those parameters that
showed significant results in GEE linear modeling. Only total macular
volume (TMV) and outer retinal layers (ORL) thickness were related to
clinical disease severity SARA score), but significance depended on the
single more severely ataxic subject. Statistics come from generalized
estimating equations. B, non-standardized correlation coefficient; SE,
standard error
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contents of [45]). We assume that the high rates of fixation
loss and the concurrent low reliability indices in the visual
field tests are indicators of reduced processing speed in
SCA-PRKCG patients and that these problems may partially
explain reduced contrast sensitivity and vision-related quality
of life. Regarding statistical analysis, we do not believe that
different modes of statistical evaluation, namely the MWU
test as a non-parametric rank-sum test for binocular visual
acuity on the one hand and the semiparametric GEE for the
monocular visual acuity on the other hand, were responsible
for the significant binocular but not monocular between-group
differences in visual acuity. GEEs were performed to account
for more than one inner-subject variable and increase the pow-
er of the statistic evaluation. Hence, GEEs are considered even
more sensitive in detecting between-group differences than
rank-sum tests.
With respect to visual pathway affection, we acquired OCT
images. This did not reveal structural retinal changes in SCA-
PRKCG. In addition, there was no significant difference in
layer segmentation analysis in comparison to the HC group.
More specifically, values in pRNFL were numerically even
slightly higher in the SCA-PRKCG group. A non-significant
difference in this range cannot be considered thickening and
should not be overinterpreted given the small number of pa-
tients. However, it should be mentioned that the thickening of
the pRNFL may indicate papilledema in an inflammatory af-
fection of the optic nerve. Furthermore, PKCγ-knockout mice
show an increased thickness of the inner nuclear layer and
ganglion cell layer due to large vacuoles between cells, while
the total number of nuclei was reduced in these layers [17],
and vacuoles may not be visible with OCT. Moreover, retinas
of these mice have an increased sensitivity for oxidative stress,
which causes decreased outer nuclear layer thickness [17].
However, PKCγ-knockout mice are not considered a suitable
model for SCA-PRKCG as a toxic gain of function (and not
loss of function) is supposed to cause SCA-PRKCG.
Unfortunately, the two histopathological reports of SCA-
PRKCG to date did not report on retinal findings [61, 62].
Hence, although retinal atrophy due to SCA-PRKCG is highly
unlikely according to our findings, there remains uncertainty
about a possible increase of retinal layer thickness in SCA-
PRKCG and its histopathological and functional correlates.
Taken together, our OCT data rather rule out retinal thinning
as a feature of SCA-PRKCG and differ from results of earlier
studies in other SCA types: Stricker et al. detected pRNFL
thinning of the temporal quadrant and visual acuity reduction
in SCA-ATXN1 [33]. Pula et al. found reduced pRNFL thick-
ness in SCA-ATXN2 and SCA-ATXN3 but not in SCA-
ATXN1 and a reduced TMV in SCA-ATXN1, SCA-
ATXN3, and SCA-CACNA1A [26]. Alvarez et al. described
a reduced pRNFL thickness without a specific pattern of thin-
ning in sector analysis in SCA-ATXN3. None of the studies
has analyzed intra-retinal layer thickness of the macula. It is
important to note that Pula et al. and Alvarez et al. reported a
correlation between disease severity and pRNFL thinning for
SCA-ATXN2 and SCA-ATXN3 or SCA-ATXN3 alone [26,
34], but data were limited to small sample sizes. Both studies
did not report visual acuity for their cohort. In conclusion,
studies evaluating vision-related quality of life indicate a re-
duction in SCA patients, irrespective of the specific genotype,
and, if assessed, visual acuity seems to be reduced in SCA
cohorts in general. Reports of retinal and optic nerve involve-
ment are inconsistent even within the same SCA subtypes but
these data are limited to small patient groups which are not
homogenous regarding disease duration, disease severity, and
methods of examination.
In the absence of visible morphological retinal changes in
the SCA-PRKCG cohort, functional deficits might be based
on ultrastructural changes and there is some support to this
hypothesis: The PKCγ is only expressed in a small amount of
cells in the retina and the subsequent structures of the visual
pathway [13, 16] especially in cells of the magnocellular vi-
sual system [13]. Even a complete loss of these cells might not
be detectable in OCT images or become apparent in between-
group comparisons of retinal layer thickness. Interestingly, the
magnocellular visual system is responsible for the detection of
movement and contrast sensitivity, while the parvocellular
system is important for color vision. This is interesting be-
cause most subscores of the NEI-VFQ were worse in the
SCA-PRKCG cohort while color vision was preserved, which
would be in line with an affection of the magnocellular visual
pathway in SCA-PRKCG.
In the mouse cerebellum, mutant PKCγ impedes the prun-
ing of surplus synapses leading to dysfunctional synapses and
localized Purkinje cell loss [63]. Again, a similar pattern of
damage in the visual pathway—dysfunctional synapses and
localized atrophy—could have been missed by OCT. Of note,
cross-sectional inspection of structural brain MRI in the cur-
rent SCA-PRKCG cohort did not support progression of cer-
ebellar atrophy with longer-standing disease (despite progres-
sion of ataxia symptoms), but revealed the presence of cere-
bellar atrophy even years before the manifestation of ataxia in
one case [45]. A similar mismatch of structural findings and
patient’s functions seems also possible at the level of the ret-
ina. However, given the limitations when interpreting the vi-
sual contrast sensitivity results, the hypothesis of an ultrastruc-
tural damage of the visual pathway in SCA-PRKCG is highly
hypothetical and needs further evaluation. Histopathological
analysis of the retina in SCA-PRKCG patients would be par-
ticularly important, e.g., to search for retinal pericellular vac-
uoles and pathology of PRKCγ-expressing cell types.
Finally, oculomotor deficits may serve as an explanation of
reduced visual acuity and vision-related quality of life. In our
opinion, difficulties in alignment are the most probable expla-
nation, why binocular but not monocular visual acuity results
are reduced in SCA-PRKCG patients compared with HC.
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Furthermore, oculomotor deficits serve as an explanation for
the high rate of fixation loss in the visual field tests.
Oculomotor deficits—at least saccadic eye movements—were
seen in every patient of the SCA-PRKCG cohort. However,
while abnormal VORmight reduce visual acuity during motion
[64], visual acuity and contrast sensitivity were assessed in a
static manner in the current study. Moreover, VOR alteration
was only described in two patients and disturbed suppression of
fixation was unrelated to worse contrast sensitivity results.
Oscillopsia was only prominent in three patients, all of them
presenting with normal contrast sensitivity and visual acuity
results. Likewise, patients withmoderate to severe/constant dip-
lopia presented normal contrast sensitivity tests. In conclusion,
we did not find one specific oculomotor deficit, which could
explain the reduced binocular visual acuity or vision-related
quality of life in PRKCG patients. Nonetheless, even if those
deficits might not explain reduced visual acuity, the total impact
of all oculomotor and alignment deficits (e.g., diplopia,
oscillopsia) together may contribute to the reduced vision-
related quality of life in SCA-PRKCG patients.
This hypothesis is corroborated by findings in other SCAs:
Kedar et al. described a reduced vision-related quality of life
in an ataxia cohort of 19 patients suffering from SCA-ATXN1,
SCA-ATXN3, or SCA-CACNA1Awith reduced scores com-
pared with established normative data of NEI-VFQ. They also
found a reduced binocular contrast sensitivity in the SCA
cohort. Furthermore, patient self-report indicated disturbance
of near-, distance-, and peripheral vision, as was the case in
our study. The authors hypothesized that reduced vision-
related quality of life in SCA may be generally caused by
“ocular motility and alignment deficits” [20]. However, as
opposed to study, monocular and binocular high-contrast vi-
sual acuity was unimpaired.
Reduced low-contrast sensitivity or visual acuity was de-
scribed in several neurodegenerative disorders such as
Parkinson’s disease, Friedreich ataxia, or even spinocerebellar
ataxias [20, 65, 66]. However, in nearly all of these diseases, a
concomitant affection of the afferent visual pathway was de-
tected as a causal factor for visual acuity deficits. Rabiah et al.
found reduced visual acuity results in a mixed ataxia cohort in
only 16% of patients [67], which again supports that ataxia
does not automatically lead to reduced visual acuity.
In sum, we conclude that reduced visual acuity results in
SCA-PRKCG patients are of multifactorial nature. Technical
issues, concomitant diseases (depression, cognitive impair-
ment, reduced information processing speed), and oculomotor
deficits might contribute to visual impairment.
Regarding the vision-related quality of life, we also have to
take into account that this is a subjective measure which does
not necessarily reflect standard visual function tests. This was
seen in patients with idiopathic infantile nystagmus
syndrome—as an example of an isolated oculomotor deficit
syndrome—who showed reduced vision-related quality of life
without concordant changes in visual acuity measurements
[68]. Again, mood disorders may result in an overestimation
of the visual impairment. While the differentiated self-
assessment with preserved dimensions of general vision, well-
being, and color vision or ocular pain argues strongly against
this hypothesis, patients might misinterpret or even ig-
nore their actual visual deficits. Especially patients with
neurological deficits might underestimate their visual
deficits [69].
While this study provides the first systematic description of
visual disturbances in a SCA-PRKCG cohort, it has several
limitations. Firstly, due to the rarity of SCA-PRKCG, only a
small number of patients were included. Secondly, we ran a
large number of tests in an exploratory approach; hence, sig-
nificant results have to be interpreted with caution. Thirdly, we
did not perform electrophysiological examinations in our pa-
tients. Electroretinography (ERG) might have helped to better
detect and localize deficits in the afferent visual system of
SCA-PRKCG patients. MRI and especially diffusion tensor
imaging (DTI) could help to evaluate the microstructural in-
tegrity of the posterior visual pathway [70].
Finally, we describe one patient, who suffered from ataxia
but carried a VUS in the catalytic domain of PRKCG
(R634H). While mutations in the catalytic domain are less
common than in the regulatory domain of PKCγ, the pheno-
type has been suggested as more complex [8]. Interestingly,
this patient was the only patient in our cohort with a remark-
able pathology in both fundus images, more precisely an
epitheliopathy of unknown origin. The etiology of
epitheliopathies comprises a wide range of differential diag-
noses from age-related macular degeneration to hereditary
diseases [71]. A cone-rod dystrophy is a characteristic symp-
tom of SCA-ATXN7 [23] and involvement of the photorecep-
tor layer has been linked to SCA-ATXN1 [72]. In the light of
unremarkable retinal findings in all confirmed SCA-PRKCG
patients reported here, this may either suggest a different ge-
notype than SCA-PRKCG for this case, which is also support-
ed by structural brain MRI findings [45] or a specific (retinal)
phenotype that has hitherto not been reported.
There is increasing evidence that patients with
spinocerebellar ataxias suffer from a reduced vision-related
quali ty of life. However, due to the diversity in
pathomechanisms and systems affected in different SCA ge-
notypes, the clinical correlate of this finding remains unclear.
A larger sample size of different SCA patients will help to
better segregate between oculomotor deficits and retinal
changes as a putat ive cause of reduced VRQoL.
Furthermore, as some SCAs may share a common
pathomechanism as suggested for SCA-PRKCG and SCA-
ATXN1 [21], elucidation of visual impairment in one of those
diseases could help to better understand SCAs in general and
delineate possibly common pathways that lead to visual im-
pairment in SCAs.
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For SCA-PRKCG, OCT data rather rule out retinal atrophy
as a contributor to visual impairment and reduced VRQoL.
Multiple factors might contribute to lower test results for bin-
ocular visual acuity and vision-related quality of life such as
concomitant diseases, especially depression, cognitive impair-
ment, and oculomotor misalignment as well as technical is-
sues for visual acuity testing (e.g., habitual correction, selec-
tion bias). Further studies should evaluate ultrastructural
changes in the visual pathway of SCA-PRKCG patients.
Conclusion
In this pilot study, we investigated visual impairment in a
cohort of SCA-PRKCG patients. While patients with SCA-
PRKCG showed lower binocular, but not monocular visual
acuity for high- and low-contrast and lower vision-related
quality of life compared with age- and sex-matched healthy
controls, we found no changes in the retinal structure on OCT.
Hence, in contrast to other SCAs, we can rule out a
maculopathy or retinal thinning as a cause of reduced
vision-related quality of life in SCA-PRKCG patients.
Concomitant diseases, oculomotor deficits, and cognitive im-
pairment might serve as explanations for the reduced contrast
sensitivity in the current cohort.
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